Go or no go? Pandemic looms over FDA timelines
Approval decisions are due for Jazz, Gilead and Galapagos in July, while Glaxo is preparing for a panel.
Gilead finally prices its Covid-19 drug
By pricing remdesivir at $2,340 for a five-day course Gilead has kept investors on side, but others will be disappointed.
Sanofi’s third Translate collaboration sees big bucks at last
The deal-hungry French big pharma gives Translate’s mRNA vaccine technology a massive boost.
The FDA gets aggressive with Covid-19 antibody tests
Chembio’s antibody test is the first to have its authorisation revoked. It might not be the last.
Big pharma sports smallest late-stage pipeline for a decade
The number of novel, pivotal-stage projects in big pharma pipelines has plunged – just as Covid-19 put the brakes on deal making.
Germany stakes its claim over Curevac
The German government will not get exclusive access to Curevac’s Covid-19 vaccine as part of its 23% stake purchase, the company insists.
The importance of testing Covid-19 tests
The US is authorising new Covid-19 antibody tests faster than it is checking their accuracy.
Here come the anti-Covid antibodies
Behind Lilly’s LY-CoV555 come numerous biopharma antibody projects bidding to enter clinical development.
Healthineers’ Covid-19 antibody test spikes an interest in vaccines
The German group has come late to antibody testing, but has punchy accuracy data and a possible means of neutralising some of the competition.
Go or no go? Pandemic looms over FDA timelines
Approval decisions are due for Jazz, Gilead and Galapagos in July, while Glaxo is preparing for a panel.
Gilead finally prices its Covid-19 drug
By pricing remdesivir at $2,340 for a five-day course Gilead has kept investors on side, but others will be disappointed.
Sanofi’s third Translate collaboration sees big bucks at last
The deal-hungry French big pharma gives Translate’s mRNA vaccine technology a massive boost.
The FDA gets aggressive with Covid-19 antibody tests
Chembio’s antibody test is the first to have its authorisation revoked. It might not be the last.
Big pharma sports smallest late-stage pipeline for a decade
The number of novel, pivotal-stage projects in big pharma pipelines has plunged – just as Covid-19 put the brakes on deal making.
Germany stakes its claim over Curevac
The German government will not get exclusive access to Curevac’s Covid-19 vaccine as part of its 23% stake purchase, the company insists.
